The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed Amendment No. 2 to a Schedule 13G with the SEC, disclosing beneficial ownership of common stock in Karyopharm Therapeutics Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Both reporting persons each disclosed 203,129.41 shares of Karyopharm Therapeutics common stock beneficially owned.
  • Percent of class: The disclosed position represents 0.9% of Karyopharm Therapeutics' outstanding common stock.
  • Shared voting power: Goldman Sachs entities reported shared voting power over 203,126.41 shares, with zero sole voting power.
  • Shared dispositive power: Both entities reported shared dispositive power over 203,129.41 shares, with zero sole dispositive power.
  • Event date: The filing event triggering this amendment was September 30, 2026.
  • Ordinary course certification: The filing certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Goldman Sachs Entities Disclose Sub-1% Position in Karyopharm as of September 30, 2026

According to the filing, The Goldman Sachs Group, Inc. (a Delaware holding company) and Goldman Sachs & Co. LLC (organized in New York) jointly submitted Amendment No. 2 to Schedule 13G covering Common Stock of Karyopharm Therapeutics Inc. (CUSIP 48576U205), with par value of $0.0001 per share. The triggering event date is listed as September 30, 2026, and the filing was signed by Ameen Soetan, identified as attorney-in-fact for both entities, on October 8, 2026.

The filing reports that each of the two Goldman Sachs entities beneficially owns 203,129.41 shares in aggregate, representing 0.9% of the class. Neither entity holds sole voting or sole dispositive power; shared voting power is reported at 203,126.41 shares and shared dispositive power at 203,129.41 shares for both. The Goldman Sachs Group, Inc. is classified as a parent holding company (HC) and corporation (CO), while Goldman Sachs & Co. LLC is classified as a broker-dealer (BD), other entity (OO), and investment adviser (IA).

Exhibit 99.2 of the filing states that the reported securities "are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC," described as a subsidiary of The Goldman Sachs Group, Inc. and registered as both a broker-dealer and an investment adviser. Exhibit 99.3 further notes that the filing "reflects the securities beneficially owned by certain operating units (collectively, the 'Goldman Sachs Reporting Units')" and that those units "disclaim beneficial ownership" of securities held in certain client accounts and investment entities, in accordance with SEC Release No. 34-39538.

What Was Disclosed

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly amended their Schedule 13G to report 203,129.41 shares, or 0.9%, of Karyopharm Therapeutics common stock beneficially owned as of September 30, 2026, with no sole voting or dispositive power held by either entity.